Author Archives for Adeline Chauvigné

Atlantic Bone Screen, a new website

Atlantic Bone Screen is pleased to present you its new website! New design, new content, new technology… it illustrates our... View Article

Rédigé par Adeline Chauvigné, le 2016-11-07

Atlantic Bone Screen, a new website

Atlantic Bone Screen is pleased to present you its new website! New design, new content, new technology… it illustrates our... View Article

GE Healthcare and Valneva : new delivery for Vaccine Production

GE Healthcare and Valneva Collaboration Delivers Optimized Cell Culture Medium for Vaccine Production  + Collaboration jointly developed a new medium optimized... View Article

Florence Hallouin is appointed Deputy Director of Atlanpole Biotherapies Cluster

Florence HALLOUIN is appointed Deputy Director of Atlanpole Biotherapies.  She ensures the operational coordination of the Cluster, relationships with its partners... View Article

Rédigé par Adeline Chauvigné, le 2016-10-03

Florence Hallouin is appointed Deputy Director of Atlanpole Biotherapies Cluster

Florence HALLOUIN is appointed Deputy Director of Atlanpole Biotherapies.  She ensures the operational coordination of the Cluster, relationships with its partners... View Article

CESTI IHU: innovative strategies of tolerance induction in the transplanted patient

This research program, led by Dr. Sophie Conchon (CRTI – Inserm 1064 – ITUN) uses the specific immunological properties of... View Article

Rédigé par Adeline Chauvigné, le 2016-10-03

CESTI IHU: innovative strategies of tolerance induction in the transplanted patient

This research program, led by Dr. Sophie Conchon (CRTI – Inserm 1064 – ITUN) uses the specific immunological properties of... View Article

Affilogic signs with Takeda global pharma

Takeda and Affilogic entered into a research collaboration to develop therapies based on Nanofitines® in the central nervous system …... View Article

Rédigé par Adeline Chauvigné, le 2016-10-03

Affilogic signs with Takeda global pharma

Takeda and Affilogic entered into a research collaboration to develop therapies based on Nanofitines® in the central nervous system …... View Article

ARRONAX PLUS: NEW TOOLS TO ENRICH THE NUCLEAR ARSENAL AGAINST CANCER

   The objective in nuclear medicine (imaging and therapy) is to build up both a world-class research group and eventually... View Article

Rédigé par Adeline Chauvigné, le 2016-10-03

ARRONAX PLUS: NEW TOOLS TO ENRICH THE NUCLEAR ARSENAL AGAINST CANCER

   The objective in nuclear medicine (imaging and therapy) is to build up both a world-class research group and eventually... View Article

BIOREGATE FORUM: A GREAT SUCCESS!

In September in Nantes, an International Forum dedicated to regenerative medicine was held, bringing together 180 participants. Based on the... View Article

Rédigé par Adeline Chauvigné, le 2016-10-10

BIOREGATE FORUM: A GREAT SUCCESS!

In September in Nantes, an International Forum dedicated to regenerative medicine was held, bringing together 180 participants. Based on the... View Article

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article

OSE Immunotherapeutics : exercise of option within global license agreement with Janssen

OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation... View Article

OGD2 Pharma and Green Cross LabCell start collaboration

OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes France & Seoul... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

OGD2 Pharma and Green Cross LabCell start collaboration

OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes France & Seoul... View Article